Patients with resected head and neck cancers may benefit clinically from an investigational personalized vaccine.

Published Date: 10 Apr 2024

Patients with surgically removed HPV-negative head and neck squamous cell cancer (HNSCC) experienced low rates of disease relapse after receiving the personalized neoantigen vaccine TG4050, which stimulated tumor-specific immune responses.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

2.

The main subject is associated with suicide in the United States.

3.

Alkem introduces cetuximab under the trade name Cetuxa in India.

4.

Firefighters who eat better can combat cancer.

5.

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot